TR200100889T2 - Disfosfonik asit içeren terkipler - Google Patents

Disfosfonik asit içeren terkipler

Info

Publication number
TR200100889T2
TR200100889T2 TR2001/00889T TR200100889T TR200100889T2 TR 200100889 T2 TR200100889 T2 TR 200100889T2 TR 2001/00889 T TR2001/00889 T TR 2001/00889T TR 200100889 T TR200100889 T TR 200100889T TR 200100889 T2 TR200100889 T2 TR 200100889T2
Authority
TR
Turkey
Prior art keywords
acid
dysphosphonic
compositions containing
dosage form
composition
Prior art date
Application number
TR2001/00889T
Other languages
English (en)
Inventor
Gabel Rolf-Dieter
Preis Walter
Woog Heinrich
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200100889(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200100889T2 publication Critical patent/TR200100889T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

Mevcut bulus farmasötik bir terkibe ve bu terkibin hazirlanmasi için bir isleme iliskindir. Terkip kati birim dozaj seklindedir, söz konusu dozaj seklinin özelligi asagidakileri içermesidir. . bir iç faz, bu iç faz aktif bilesen olarak difosfonik asit veya bunun fizyolojik açidan uygun bir tuzunu içerir, dozajdaki aktif madde miktari yaklasik 0.25 ila yaklasik 100 mg arasindadir .bir dis faz,bu dis faz söz konusu dozaj seklinin agirligina göre agirlik itibariyla yaklasik %5'ten az stearik asit içerir.
TR2001/00889T 1998-10-09 1999-10-01 Disfosfonik asit içeren terkipler TR200100889T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119102A EP0998932A1 (de) 1998-10-09 1998-10-09 Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
TR200100889T2 true TR200100889T2 (tr) 2001-07-23

Family

ID=8232769

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00889T TR200100889T2 (tr) 1998-10-09 1999-10-01 Disfosfonik asit içeren terkipler

Country Status (35)

Country Link
US (2) US6294196B1 (tr)
EP (2) EP0998932A1 (tr)
JP (2) JP4471498B2 (tr)
KR (1) KR100522505B1 (tr)
CN (1) CN1150000C (tr)
AR (3) AR014081A1 (tr)
AT (1) ATE311887T1 (tr)
AU (1) AU752532B2 (tr)
BR (1) BR9914367A (tr)
CA (1) CA2346662C (tr)
CO (1) CO5050325A1 (tr)
CY (1) CY1105437T1 (tr)
CZ (1) CZ299008B6 (tr)
DE (1) DE69928819T2 (tr)
DK (1) DK1117412T3 (tr)
ES (1) ES2253919T3 (tr)
HK (1) HK1040914B (tr)
HR (1) HRP20010243B1 (tr)
HU (1) HU226457B1 (tr)
ID (1) ID29876A (tr)
IL (3) IL141912A0 (tr)
MA (1) MA27123A1 (tr)
ME (1) ME00637B (tr)
MY (1) MY126625A (tr)
NO (1) NO327447B1 (tr)
NZ (1) NZ510433A (tr)
PE (1) PE20001082A1 (tr)
PL (1) PL194552B1 (tr)
RS (1) RS49809B (tr)
RU (1) RU2207860C2 (tr)
SI (1) SI1117412T1 (tr)
TR (1) TR200100889T2 (tr)
TW (1) TW576742B (tr)
WO (1) WO2000021540A1 (tr)
ZA (1) ZA200102276B (tr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
HUP0402267A3 (en) * 2001-12-21 2007-05-29 Procter & Gamble Method for treatment of bone disorders
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
EA006053B1 (ru) * 2001-12-24 2005-08-25 Тева Фармасьютикал Индастриес Лтд. Твёрдая лекарственная форма, способ её изготовления и устройство
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
ES2530791T3 (es) † 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
AU2006222690B2 (en) * 2002-12-20 2009-04-23 F. Hoffmann-La Roche Ag High dose ibandronate formulation
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1709968A1 (en) * 2004-01-30 2006-10-11 Astellas Pharma Inc. P2x receptor inhibitor
ES2358269T3 (es) * 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
LT2662380T (lt) * 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
EP2610261A1 (en) * 2005-02-01 2013-07-03 F. Hoffmann-La Roche AG Ibandronate polymorph B
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
EP2114455A4 (en) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc PHARMACEUTICAL COMPOSITION USING A HOT-MELT GRANULATED AGENT
EP2298286B8 (en) * 2009-09-18 2017-08-09 SiTec PharmaBio SL Process for dewatering of product powders
KR101244414B1 (ko) * 2010-11-05 2013-03-18 주식회사 바이오파마티스 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
EP2661262B1 (en) 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
US4798725A (en) 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
DE3767998D1 (de) * 1986-12-20 1991-03-14 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
FR2629716B1 (fr) 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
EP0583470A4 (en) 1992-01-10 1995-07-26 Obschestvo S Ogranichennoy Otv PHARMACEUTICAL COMPOSITION IN GRANULATE FORM AND PRODUCTION METHOD.
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE4228552A1 (de) 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
CZ287984B6 (cs) 1993-05-15 2001-03-14 Roche Diagnostics Gmbh Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
HUP0103931A3 (en) 2003-01-28
DE69928819T2 (de) 2006-07-20
AU6467599A (en) 2000-05-01
HRP20010243A2 (en) 2002-04-30
CZ299008B6 (cs) 2008-04-02
RS49809B (sr) 2008-08-07
IL177940A0 (en) 2006-12-31
HRP20010243B1 (hr) 2011-02-28
SI1117412T1 (sl) 2006-04-30
IL141912A0 (en) 2002-03-10
HUP0103931A2 (en) 2002-06-29
HU226457B1 (en) 2008-12-29
ES2253919T3 (es) 2006-06-01
CO5050325A1 (es) 2001-06-27
NO20011714D0 (no) 2001-04-05
RU2207860C2 (ru) 2003-07-10
YU20501A (sh) 2003-02-28
HK1040914A1 (en) 2002-06-28
ZA200102276B (en) 2002-06-19
AR014081A1 (es) 2001-01-31
IL177940A (en) 2012-05-31
ATE311887T1 (de) 2005-12-15
PL194552B1 (pl) 2007-06-29
ME00637B (me) 2008-08-07
CN1319015A (zh) 2001-10-24
KR20010073203A (ko) 2001-07-31
CZ20011233A3 (cs) 2001-09-12
NO327447B1 (no) 2009-06-29
JP2002527398A (ja) 2002-08-27
EP1117412B1 (en) 2005-12-07
ID29876A (id) 2001-10-18
AU752532B2 (en) 2002-09-19
HK1040914B (zh) 2004-12-10
CY1105437T1 (el) 2010-04-28
CA2346662A1 (en) 2000-04-20
NO20011714L (no) 2001-04-05
JP4471498B2 (ja) 2010-06-02
AR047815A2 (es) 2006-02-22
MY126625A (en) 2006-10-31
NZ510433A (en) 2003-08-29
KR100522505B1 (ko) 2005-10-18
IL141912A (en) 2006-12-10
US6627221B2 (en) 2003-09-30
US20020006441A1 (en) 2002-01-17
MA27123A1 (fr) 2005-01-03
CA2346662C (en) 2006-05-09
EP0998932A1 (de) 2000-05-10
PL347243A1 (en) 2002-03-25
CN1150000C (zh) 2004-05-19
BR9914367A (pt) 2001-06-26
EP1117412A1 (en) 2001-07-25
DK1117412T3 (da) 2006-04-03
DE69928819D1 (de) 2006-01-12
JP2010116408A (ja) 2010-05-27
WO2000021540A1 (en) 2000-04-20
TW576742B (en) 2004-02-21
PE20001082A1 (es) 2000-10-18
US6294196B1 (en) 2001-09-25
AR069942A2 (es) 2010-03-03

Similar Documents

Publication Publication Date Title
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
EA200600884A1 (ru) Композиции комплексов экстроген-циклодекстрин
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
TR199801530T2 (tr) VEGF Inhibitörleri olarak kinazolin türevleri.
TR199801115T2 (tr) Kinazolin türevleri.
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
TR200002853T2 (tr) Antitümör etkili indolil-3-glioksilik asit türevleri
ES2029769A6 (es) Procedimiento para preparar medicamentos a base de acidos carboxilicos que contienen azufre como sustancia activa.
MA26960A1 (fr) Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation
BG98793A (bg) Нови производни на аминокиселините,методи за тяхното получаване и фармацевтични състави,съдържащи тези съединения
TR200103153T2 (tr) Yeni bileşimler
ATE158504T1 (de) Brausemischungen enthaltend ibuprofen und verfahren
ATE347563T1 (de) Il-6-antagonist peptide
GB9718568D0 (en) Compositions
IL131216A (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
PT1121109E (pt) Formulacao bifasica contendo tramadol
ZA202404160B (en) Oral solution containing lisdexamfetamine and process for the preparation thereof
RU99118510A (ru) Композиция для лечения или предупреждения рака простаты
KR910004192A (ko) 프로페니토인의 치료적 유효량을 함유하는 발작증 치료용 제약 조성물
MY102368A (en) Solid sustained-release composition
KR910002789A (ko) 아크릴산염, 이것의 제조방법, 이것을 함유한 제약조성물 및 의약에서 이것을 사용하는 방법
EP0817643A4 (en) SUBSTANCES AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES